A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma - Trial NCT06049030
Access comprehensive clinical trial information for NCT06049030 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 190 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 1
Sep 25, 2023
Sep 25, 2025
Primary Outcome
Phase Ia: MTD/MAD of HS-10516,Phase Ib: Objective Response Rate (ORR) by Independent Review Committee (IRC)
Summary
The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum
 acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary
 efficacy of HS-10516 in ccRCC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06049030
Non-Device Trial